<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3013">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067675</url>
  </required_header>
  <id_info>
    <org_study_id>Triton RDB</org_study_id>
    <nct_id>NCT03067675</nct_id>
  </id_info>
  <brief_title>Triton Reference Database</brief_title>
  <official_title>Topcon DRI OCT Triton Reference Database Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect OCT measurement data on normal healthy eyes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to collect OCT measurement data on normal healthy eyes in
      order to determine the reference limits for Topcon DRI OCT Triton based on the percentile
      points for 1%, 5%, 95%, and 99%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>1 Minute</time_frame>
    <description>The thickness of the macula layer</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Healthy Eyes</condition>
  <arm_group>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
    <description>Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Topcon DRI OCT Triton (plus)</intervention_name>
    <description>OCT Machine used for diagnostic purposes</description>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subject population will consist of subjects without eye disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate
             as evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes bilaterally (cataracts are
             acceptable)

          4. IOP â‰¤ 21 mmHg bilaterally

          5. BCVA 20/40 or better bilaterally

        Exclusion Criteria

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses &gt; 20% or false positives &gt;
             33%, or false negatives &gt; 33%

          4. Visual field defects consistent with glaucomatous optic nerve damage based on at
             least one of the following two findings:

               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1
                  of which is depressed below the 1% level;

               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;

          5. Narrow angle

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Riesman, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danny Leung, BS</last_name>
    <phone>(925)245-7734</phone>
    <email>dleung@topcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California College of Optometry</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92760</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Parker</last_name>
      <phone>714-463-7580</phone>
      <email>sparker@ketchum.edu</email>
    </contact>
    <investigator>
      <last_name>George Comer, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accessoreyes Optometry</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elda Mehrabyan, OD</last_name>
      <phone>626-577-8881</phone>
      <email>info@accessoreyesoptometry.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse Nylin</last_name>
      <phone>312-949-7298</phone>
      <email>Enylin@ico.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Chaglasian, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York VA</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chou Jefferey, OD</last_name>
      <email>jeffchou.od@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Murray Fingeret, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stat University of New York College of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Leung</last_name>
      <phone>212-938-4052</phone>
      <email>clinicresearch@sunyopt.edu</email>
    </contact>
    <investigator>
      <last_name>Mitch Dul, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>February 24, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>no known ocular pathology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
